Business
Regen BioPharma, Inc. Program to Determine the 3-D Crystal Structure of NR2F6 Progresses to Next Step
Regen BioPharma, Inc. Program to Determine the 3-D Crystal Structure of NR2F6 Progresses to Next Step.
About this update from Regen Biopharma, Inc.
[{"type":"text","content":"\n\n\n\nRegen BioPharma, Inc. Program to Determine the 3-D Crystal Structure of NR2F6 Progresses to Next Step\n\n\n\n\n\nRegen BioPharma, Inc. Program to Determine the 3-D Crystal Structure of NR2F6 Progresses to Next Step\nPR Newswire\nSAN DIEGO, February 21, 2018\n\n\n\nSAN DIEGO, February 21, 2018 /PRNewswire/ --\n\nRegen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has moved into the second stage of its previously-announced program to determine the three-dimensional structure of NR2F6 - with and without its proprietary small molecule drugs bound to it. The object of this structure-determination program is to shed light on how the small molecules bind to and modulate NR2F6 activity.\n\nDetermining the X-ray crystal structure of a protein and its ligand is a multi-step process:  \n\n\nHigh levels of the protein are expressed.  \n\nA saturated solution of protein is created in the presence of ligand. If the protein of interest has never been structurally determined before (as in the case of NR2F6), scores of different conditions must be tested. High levels of protein are needed in the first step, because ample protein is required to saturate a solution and to test many different conditions.  \n\nFinally, if crystals form, their structural features are determined. This is done by exposing the crystals to a very high-power x-ray beam. The x-ray beam hits the protein and diffracts. The pattern of diffraction is used to determine the structure.\n\n\n\"We are making good progress in the crystallization phase of the process of x-ray structure determination. Crystals produced during the third step must be of high quality to be useable for structure determination,\" says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen.\n\n\"We are pleased this program continues to advance on time and are looking forward to having data that further de-risks our program,\" says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc.\n\nThe NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune sy...